EQT will buy Qiagen for $12 bln, ‌whose kits trace diseases and help police solve crimes. It’s barely more than an offer shareholders rejected back ​in 2020. Yet the Swedish buyer will ​need to grow beyond current forecasts and ⁠crank up margins to get a decent return.

Log in or sign up to comment.

No comments yet.

← Back to stories

Create FREE account

or login to continue

Signup with GoogleSignup with GitHubSignup with BlueskySignup with Blacksky
Sign up with email

Already have an account? Log in